Evidence map›Paper›PMID 35753279›Full record

ArticleDrug and alcohol dependence2022

Differences in buprenorphine treatment quality across physician provider specialties.

Jonathan S Levin, Rachel K Landis, Mark Sorbero, Andrew W Dick, Brendan Saloner, Bradley D Stein

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Examining Removal of Federal Waiver Restrictions to Prescribing Buprenorphine in Primary Care.Journal of the American Board of Family Medicine : JABFM · 2025
    Article
  3. Article
  4. Observational
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jonathan S LevinRAND Corporation, 1200 South Hayes Street, Arlington, VA, USA. Electronic address: levin@rand.org.
Rachel K LandisRAND Corporation, 1200 South Hayes Street, Arlington, VA, USA; George Washington University Trachtenberg School of Public Policy and Public Administration, Washington, DC, USA.
Mark SorberoRAND Corporation, 4570 Fifth Avenue, Suite 600, Pittsburgh, PA, USA.
Andrew W DickRAND Corporation, 20 Park Plaza, Suite 920, Boston, MA, USA.
Brendan SalonerJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Bradley D SteinRAND Corporation, 4570 Fifth Avenue, Suite 600, Pittsburgh, PA, USA; University of Pittsburgh School of Medicine, 3550 Terrace Street, Pittsburgh, PA, USA.
RAND Corporation · USJohns Hopkins University · USUniversity of Pittsburgh · US

Funding

Quality of Medication Treatment for Opioid Use Disorder in Medicaid-enrollees: The Effects of State Policies and IntiativesR01DA045800 · NIDA · RAND CORPORATION · PI STEIN, BRADLEY D · 2018 to 2022
$2.9M
Improving Access and Quality of care for Medicaid-Eligible Adults with Opioid Use DisorderK01DA042139 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SALONER, BRENDAN K · 2017 to 2021
$917k
NIDA NIH HHS K01 DA042139NIDA NIH HHS R01 DA045800
6 · The paper itself

Abstract

backgroundThe number and types of clinicians prescribing buprenorphine treatment for opioid use disorder (OUD) have increased over the past two decades, but there is little information on how potential indicators of quality of care to patients receiving buprenorphine vary by provider specialty.

methodsWe used the Medicaid Analytic eXtract from 2009 to 2014 to identify buprenorphine treatment episodes. We assigned physician specialties to episodes based on whether an episode had at least one outpatient claim linked to specialists in addiction, behavioral health, opioid treatment program (OTP), pain, or primary care provider (PCP). We then used logistic regressions to estimate the association of linked physician specialty and achievement of the following process of care measures: at least 180-day duration, no co-occurring opioid analgesics, no co-occurring benzodiazepines, infectious disease screening, liver function test, drug and toxicology screenings, evaluation and management visits, and counseling.

resultsEpisodes linked to PCPs had significantly lower odds of achieving 180-day duration, an absence of opioid analgesics, an absence of benzodiazepines, drug and toxicology screenings, and counseling compared to addiction, behavioral health, and/or OTPs. Episodes linked to PCPs had significantly higher odds of undergoing infectious disease screenings, liver function tests, and evaluation and management visits compared to all specialty categories.

conclusionsEpisodes were more likely to achieve process of care measures related to the specialties of their physicians, but no specialty consistently demonstrated better performance compared to PCPs. Our findings highlight the need for models that can better integrate physical and behavioral health services for OUD treatment.

Indexed as

BuprenorphineOpioid-Related DisordersPhysiciansAnalgesics, OpioidBenzodiazepinesCounselingHumansOpiate Substitution TreatmentUnited StatesAnalgesics, OpioidBenzodiazepinesBuprenorphineBuprenorphineMedicaidOpioid use disorderQuality of care

Identifiers

PMID35753279
PMCPMC10105978
OpenAlexW4281388708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.